Activity and safety of afatinib in a window preoperative EORTC study in patients with squamous cell carcinoma of the head and neck (SCCHN)
ConclusionAfatinib given for 2 weeks to newly diagnosed SCCHN patients induces a high rate of FDG-PET partial metabolic response and partial response according to RECISTv1.1. Afatinib can be safely administered before surgery. Although exploratory, the hypoxic gene signature needs further investigations as a predictive biomark er of afatinib activity.Clinical trial registrationClinicalTrials.gov: NCT01538381
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer & Oncology | Carcinoma | Clinical Trials | Genetics | MRI Scan | PET Scan | Renal Failure | Skin Cancer | Squamous Cell Carcinoma | Study | Toxicology